| Drug General Information |
| Drug ID |
D01OKE
|
| Former ID |
DNC011936
|
| Drug Name |
NILVADIPINE
|
| Drug Type |
Small molecular drug
|
| Indication |
Discovery agent
|
Phase 3 |
[1]
|
|---|
| Structure |
|
Download
2D MOL
3D MOL
|
| Formula |
C19H19N3O6
|
| Canonical SMILES |
CC1=C(C(C(=C(N1)C#N)C(=O)OC)C2=CC(=CC=C2)[N+](=O)[O-])C<br />(=O)OC(C)C
|
| InChI |
1S/C19H19N3O6/c1-10(2)28-19(24)15-11(3)21-14(9-20)17(18(23)27-4)16(15)12-6-5-7-13(8-12)22(25)26/h5-8,10,16,21H,1-4H3
|
| InChIKey |
FAIIFDPAEUKBEP-UHFFFAOYSA-N
|
| CAS Number |
CAS 75530-68-6
|
| PubChem Compound ID |
|
| SuperDrug ATC ID |
C08CA10
|
| Target and Pathway |
| Target(s) |
Voltage-dependent L-type calcium channel alpha-1D subunit |
Target Info |
Inhibitor |
[2]
|
|---|
| Voltage-dependent L-type calcium channel subunit alpha-1C |
Target Info |
Inhibitor |
[2]
|
|
KEGG Pathway
|
MAPK signaling pathway
|
|
Calcium signaling pathway
|
|
cGMP-PKG signaling pathway
|
|
cAMP signaling pathway
|
|
Cardiac muscle contraction
|
|
Adrenergic signaling in cardiomyocytes
|
|
Vascular smooth muscle contraction
|
|
Circadian entrainment
|
|
Retrograde endocannabinoid signaling
|
|
Glutamatergic synapse
|
|
Cholinergic synapse
|
|
Serotonergic synapse
|
|
GABAergic synapse
|
|
Dopaminergic synapse
|
|
Insulin secretion
|
|
GnRH signaling pathway
|
|
Oxytocin signaling pathway
|
|
Type II diabetes mellitus
|
|
Carbohydrate digestion and absorption
|
|
Alzheimer's disease
|
|
Amphetamine addiction
|
|
Hypertrophic cardiomyopathy (HCM)
|
|
Arrhythmogenic right ventricular cardiomyopathy (ARVC)
|
|
Dilated cardiomyopathyhsa04010:MAPK signaling pathway
|
|
Long-term potentiation
|
|
Dilated cardiomyopathy
|
|
NetPath Pathway
|
IL2 Signaling Pathway
|
|
PANTHER Pathway
|
Alzheimer disease-amyloid secretase pathway
|
|
Nicotinic acetylcholine receptor signaling pathway
|
|
5HT2 type receptor mediated signaling pathway
|
|
Beta1 adrenergic receptor signaling pathway
|
|
Beta2 adrenergic receptor signaling pathway
|
|
Oxytocin receptor mediated signaling pathwayP00003:Alzheimer disease-amyloid secretase pathway
|
|
Oxytocin receptor mediated signaling pathway
|
|
Nicotine pharmacodynamics pathway
|
|
PathWhiz Pathway
|
Muscle/Heart Contraction
|
|
Reactome
|
Adrenaline,noradrenaline inhibits insulin secretion
|
|
NCAM1 interactions
|
|
Regulation of insulin secretionR-HSA-400042:Adrenaline,noradrenaline inhibits insulin secretion
|
|
Regulation of insulin secretion
|
|
WikiPathways
|
Calcium Regulation in the Cardiac Cell
|
|
Arrhythmogenic Right Ventricular Cardiomyopathy
|
|
Alzheimers Disease
|
|
NCAM signaling for neurite out-growth
|
|
Integration of energy metabolismWP536:Calcium Regulation in the Cardiac Cell
|
|
Integration of energy metabolism
|
|
Nicotine Activity on Chromaffin Cells
|
| References |
| REF 1 | ClinicalTrials.gov (NCT02017340) A Phase III Trial of Nilvadipine to Treat Alzheimer's Disease. U.S. National Institutes of Health. |
|---|
| REF 2 | J Med Chem. 1989 Oct;32(10):2399-406.Dihydropyrimidines: novel calcium antagonists with potent and long-lasting vasodilative and antihypertensive activity. |
|---|
